Colorectal Cancer | Specialty

ASCO Releases Provisional Recommendation for RAS Testing in mCRC

October 10th 2015

ASCO has recommended extended RAS testing as a predictive biomarker of response for anti-EGFR monoclonal antibodies, further stressing the importance of broader molecular analyses for patients with metastatic colorectal cancer.

Dr. Dirk Arnold Discusses the CONSIGN Study

September 28th 2015

Dirk Arnold, MD, Director Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, Arnold Discusses the CONSIGN Study.

FDA Approves TAS-102, New Nivolumab Breakthrough Designation, Two Priority Reviews, and More

September 25th 2015

FDA Approves TAS-102 for Metastatic Colorectal Cancer

September 22nd 2015

The FDA approved the oral nucleoside TAS-102 (Lonsurf) for the treatment of patients with advanced colorectal cancer, based on results from the phase III RECOURSE trial.

USPSTF Recommends Aspirin for CRC Prevention in Draft Statement

September 17th 2015

The USPSTF has issued a draft guideline recommending the use of low-dose aspirin for the prevention of colorectal cancer and cardiovascular disease in adults aged 50 to 59 years.

Aspirin Reduces CRC Incidence in Individuals at Greatest Risk

September 15th 2015

Long-term aspirin use significantly lowered the risk of developing colorectal cancer in Lynch syndrome carriers while ameliorating the added risk associated with obesity.

Dr. Sinicrope on Mismatch Repair-Deficient Patients With Metastatic Colorectal Cancer

September 1st 2015

Frank A. Sinicrope, MD, medical oncologist, Departments of Gastroenterology and Hepatology and Oncology, Mayo Clinic, discusses patients with metastatic colorectal cancer (mCRC) who are mismatch repair-deficient.

Dr. Zafar on the Potential of Immunotherapy in Colorectal Cancer

August 31st 2015

S. Yousuf Zafar, MD, associate professor of medicine, Duke Cancer Institute, discusses the potential of immunotherapy for the treatment of patients with colorectal cancer (CRC).

Precision Medicine Modeling Helps Advance Colorectal Cancer Care

August 30th 2015

Preclinical mouse models and cell lines link colorectal cancer subtypes subtypes with potential therapies.

New FIRE-3 Analysis Shows Importance of Subsequent Therapies on mCRC Outcomes

August 28th 2015

Sequence of therapies may be more significant versus single agents in treating patients with metastatic colorectal cancer.

Coffee May Reduce Colon Cancer Recurrence by Over 40%

August 21st 2015

Charles S. Fuchs, MD, discusses a recent study which found that consuming four or more cups of coffee per day may reduce risk of recurrence by 42% and death by 34% in patients with stage III colon cancer.

Shifting the Risk-Benefit Ratio in CRC With Molecular Subtyping

August 16th 2015

Recent evidence has shed some light on the prognostic value of microsatellite instability and the potential benefit of checkpoint inhibition in colorectal cancer.

Dr. Garcia-Carbonero on Quality of Life Impact of FOLFIRI Plus Ramucirumab in mCRC

August 7th 2015

Rocio Garcia-Carbonero, MD, PhD, Universidad de Sevilla, discusses the quality of life results from the RAISE study. The RAISE study was a phase III randomized, double-blind study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal cancer (mCRC) after first-line therapy with bevacizumab, oxaliplatin, or fluoropyrimidine.

Options in Unresectable Metastatic Colorectal Cancer

July 29th 2015

Initial Treatments for Newly Diagnosed Colorectal Cancer

July 29th 2015

Communicating Test Results to Patients

July 29th 2015

Mutation Analysis in Colorectal Cancer

July 29th 2015

Biopsy for Colorectal Cancer

July 29th 2015

Discussing Genetic Testing in Colorectal Cancer

July 29th 2015

Effective Communication in Colorectal Cancer

July 29th 2015